Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLH

Lymphoma-associated hemophagocytic lympohistiocytosis is a refractory immune disorder with high mortality. Early identification and diagnosis of lymphoma-associated HLH has become the key to improve the prognosis of lymphoma-associated HLH. Therefore, we conduct a multicenter, prospective, observational clinical study to explore the sensitivity and specificity of cytokines for the early diagnosis of lymphoma-associated HLH.

Inclusion Criteria: * Adult, gender is not limited. * Patients with histopathologically confirmed lymphoma who meet HLH-04 diagnostic criteria, and did not receive systemic chemotherapy before enrollment. * Patients with histopathologically confirmed lymphoma who did not receive systemic chemotherapy before enrollment. * Informed consent obtained. Exclusion Criteria: * Patients with severe active infections (viral, bacterial, fungal, or parasitic). * Patients with active autoimmune disease or a history of organ transplantation who are receiving immunosuppressive therapy. * Patients with other type of malignant tumors within 5 years, except for cured solid tumors. * Patients planned to receive immunotherapy. * Pregnant and breastfeeding females. * History of human immunodeficiency virus (HIV) infection. * Acute or chronic active hepatitis B or hepatitis C. * Patients assessed as ineligible for the study by the investigator.